Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 12/20 | 0.76 |
| ▸ | CCR5 | P51681 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.56 |
| ▸ | EDNRA | P25101 | 1/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106483 | 0.89 | CCR4 (0.60) | CCR4CCR5EDNRA | |
| SCHEMBL5103307 | 0.89 | CCR4 (0.78) | CCR4CCR5KMT2AMEN1PABPC1 | |
| SCHEMBL5105223 | 0.86 | CCR4 (1.00) | CCR4CCR5EDNRA | |
| SCHEMBL5099483 | 0.86 | CCR5 (1.00) | CCR4CCR5KMT2AMEN1PABPC1 | |
| SCHEMBL5106108 | 0.85 | CCR5 (0.79) | CCR4CCR5KMT2AMEN1PABPC1 | |
| SCHEMBL5099419 | 0.84 | CCR4 (0.63) | CCR4CCR5KMT2AMEN1PABPC1 | |
| SCHEMBL5098574 | 0.83 | CCR4 (0.70) | CCR4CCR5KMT2AMEN1PABPC1 | |
| SCHEMBL5103322 | 0.82 | CCR5 (0.71) | CCR4CCR5KMT2AMEN1PABPC1 | |
| SCHEMBL5102857 | 0.82 | CCR4 (0.69) | CCR4CCR5KMT2AMEN1PABPC1 | |
| SCHEMBL5113238 | 0.82 | CCR5 (0.70) | CCR4CCR5KMT2AMEN1PABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410972-B2 | Compounds | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | claimed |
| EP-1458715-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2005-12-07 | — | — | EP | claimed |
| US-20050075346-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | US | claimed |
| US-7410972-B2 | Compounds | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| US-7410972-B2 | Compounds | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| US-7410972-B2 | Compounds | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| EP-1458715-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2005-12-07 | — | — | EP | disclosed |
| US-20050075346-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | US | disclosed |
| EP-1458715-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003051870-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075346-A1 | Novel compounds | CCL11, CCL2, CCL5 | CCR4 22/4885CCR5 10/4885KMT2A 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.